Personalized Medicine Research
Genomic studies combined with individual testing enables researchers to determine a patient’s susceptibility to disease, predict how they will respond to a particular drug and match them with the right therapeutics. Indeed, this new science of personalized medicine has the potential to eliminate unnecessary treatments, reduce the incidence of adverse reactions, increase drug efficacy and, ultimately, improve patient outcomes.
Implicit within this effort is the drive toward more personalized medicine using biomarkers that characterize disease severity and/or therapeutic response and particularly pharmacogenomics to target genetically identifiable response populations. New models will be used to improve existing and future therapies by generating the data that enables targeting them to susceptible populations and even individual patients who are likely to achieve the most benefit with the least adversity from specific treatments. The program involves a full partnership with (and significant contribution of resources and expertise from) Eli Lilly and Co., headquartered in Indianapolis, and the Indiana CTSI.